Therefore, combination therapies consisting of anticancer agents that exert oxidative stress together with sorafenib may prove clinically useful for treating RCC, which depends on the dsRNA-activated protein kinase-like ER kinase (PERK) pathway [78]. Here, EIF2AK3 is linked to renal cell carcinoma.